Snapshot: ASH ISTH NHF WFH Guideline Recommendations for the Management of von Willebrand Disease (VWD)
This one-page summary presents the highlights of the ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease (VWD). It outlines what is covered in the guidelines, why they matter and who they affect. Click here to access the full ASH ISTH NHF WFH VWD Guidelines.
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking, and how infusion of replacement therapy works to achieve normal levels of blood clotting. It also illustrates the clotting factor cascade and highlights the points in the cascade where each type of hemophilia treatment product […]
In the Sunday afternoon joint Laboratory Sciences and VWD Professional Development Workshop, Andra H. James explains the unique issues in the management of women with von Willebrand Disease (VWD). This talk was part of the joint Laboratory Sciences and VWD Professional Development Workshop. See below for the other talks in this workshop:
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than […]
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for […]